Journal Home
Search for

Volume 90, Issue 1, Pages 30-35 (January 2009)


View previous. 7 of 30 View next.

Pulsed dose rate brachytherapy as the sole adjuvant radiotherapy after breast-conserving surgery of T1–T2 breast cancer: First long time results from a clinical study

Bengt JohanssonaCorresponding Author Informationemail address, Leif Karlssonb, Göran Liljegrenc, Lennart Hardella, Jan Perslidenb

Received 30 January 2007; received in revised form 21 December 2007; accepted 25 February 2008. published online 14 April 2008.

Abstract 

Background and purpose

To evaluate the long time outcome with regard to local tumour control, cosmetic outcome and side effects of a short (5 days) accelerated interstitial brachytherapy treatment delivered to the surroundings of the operated sector.

Patients and methods

Between 1993 and 2003 we treated 50 women with early T1 and T2 breast cancer. Radical sector resection was performed and followed later with an interstitial pulsed dose rate (PDR) brachytherapy of 50Gy in 5 days. The treatment was centred on the tumour with a margin of 30mm. One patient was treated bilaterally. The patients were followed for a median of 86 (32–126) months.

Results

Ipsilateral breast cancer recurrence was seen in 3 patients (6%). Two of them occurred outside the treated volume. The 5- and 7-year rates of actuarial local control were 96% and 96%, respectively, overall survival 88% and 85%, disease free survival 88% and 88%, respectively. A dosimetrical analysis showed that the partial breast irradiation covered a median of 31% of the total breast volume. Fat necrosis was seen in 12% and local (moderate–strong) fibrosis in 26% of the patients. Independent cosmetic scoring showed good or excellent result in 56% of the patients.

Conclusions

Local outcome is favourable and very similar to other published studies of accelerated partial breast irradiation. Our long time cosmetic results are lower than other published results.

a Department of Oncology, Örebro University Hospital and Örebro University, Sweden

b Department of Medical Physics, and, Örebro University Hospital and Örebro University, Sweden

c Department of Surgery, Örebro University Hospital and Örebro University, Örebro, Sweden

Corresponding Author InformationCorresponding author. Department of Oncology, Örebro University Hospital and Örebro University, SE-70185 Örebro, Sweden.

PII: S0167-8140(08)00134-5

doi:10.1016/j.radonc.2008.02.022


View previous. 7 of 30 View next.